VERACYTE, INC.

Veracyte is a molecular diagnostics company that develops and performs clinical genomic tests to assist in diagnosing and treating various forms of cancer. Its primary commercial offerings include Decipher tests for prostate and bladder cancers, the Afirma classifier for thyroid nodules, and the Prosigna assay for breast cancer. The business operates through laboratory developed tests analyzed in centralized facilities as well as distributed in vitro diagnostic test kits. Its customers include physicians, endocrinologists, oncologists, hospitals, independent laboratories, and biopharmaceutical partners.

In the United States, the company operates three clinical reference laboratories located in South San Francisco, California; San Diego, California; and Austin, Texas. Outside the United States, it distributes test kits across Europe, the Middle East, Asia Pacific, Latin America, and Canada. Its diagnostic products receive reimbursement across numerous countries, including Germany, France, Spain, Italy, Canada, and Israel. The provided text notes these operating facilities but does not identify a corporate headquarters.

Summary of the business section of Veracyte's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 755 employees.”